CD79A and Miyoshi myopathy: The IMWG criteria for the therapy response and definition of minimal residual disease (MRD) recognize the Hevylite method as an additional assay for the management and monitoring of patients with oligosecretory MM (monoclonal component < 10 g/L) or with an IgA MC migrating in the β-zone of electrophoretic trace [32].